Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes

Study Questions:

Does the addition of vorapaxar, a platelet thrombin-receptor antagonist, to the treatment of acute non–ST-segment elevation myocardial infarction (NSTEMI) reduce cardiovascular ischemic event rates or improve outcomes without safety concerns?